https://ir.castlebiosciences.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/castlebiosciences/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.castlebiosciences.com/news-events/press-releases/detail/473/decisiondx-melanomas-i31-slnb-outperforms-mia-nomogram-in-identifying-patients-who-may-safely-forgo-sentinel-lymph-node-biopsy Thu, 25 Jun 26 16:30:00 -0400 https://ir.castlebiosciences.com/news-events/press-releases/detail/473/decisiondx-melanomas-i31-slnb-outperforms-mia-nomogram-in-identifying-patients-who-may-safely-forgo-sentinel-lymph-node-biopsy https://ir.castlebiosciences.com/news-events/press-releases/detail/472/castle-biosciences-chief-financial-officer-frank-stokes-named-a-2026-cfo-awards-honoree-by-the-houston-business-journal Tue, 23 Jun 26 07:00:00 -0400 https://ir.castlebiosciences.com/news-events/press-releases/detail/472/castle-biosciences-chief-financial-officer-frank-stokes-named-a-2026-cfo-awards-honoree-by-the-houston-business-journal https://ir.castlebiosciences.com/news-events/press-releases/detail/471/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 Fri, 19 Jun 26 07:00:00 -0400 https://ir.castlebiosciences.com/news-events/press-releases/detail/471/castle-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 https://ir.castlebiosciences.com/news-events/press-releases/detail/470/castle-biosciences-tissuecypher-test-surpasses-100000-orders-advancing-precision-risk-assessment-for-patients-with-barretts-esophagus Tue, 16 Jun 26 07:00:00 -0400 https://ir.castlebiosciences.com/news-events/press-releases/detail/470/castle-biosciences-tissuecypher-test-surpasses-100000-orders-advancing-precision-risk-assessment-for-patients-with-barretts-esophagus https://ir.castlebiosciences.com/news-events/press-releases/detail/469/castle-biosciences-to-present-at-the-2026-jefferies-global-healthcare-conference Wed, 13 May 26 07:00:00 -0400 https://ir.castlebiosciences.com/news-events/press-releases/detail/469/castle-biosciences-to-present-at-the-2026-jefferies-global-healthcare-conference https://ir.castlebiosciences.com/news-events/press-releases/detail/468/castle-biosciences-advancead-tx-test-receives-2026-medtech-breakthrough-award-for-genomics-innovation Tue, 12 May 26 07:00:00 -0400 https://ir.castlebiosciences.com/news-events/press-releases/detail/468/castle-biosciences-advancead-tx-test-receives-2026-medtech-breakthrough-award-for-genomics-innovation https://ir.castlebiosciences.com/news-events/press-releases/detail/467/castle-biosciences-reports-first-quarter-2026-results Wed, 06 May 26 16:05:00 -0400 https://ir.castlebiosciences.com/news-events/press-releases/detail/467/castle-biosciences-reports-first-quarter-2026-results https://ir.castlebiosciences.com/news-events/press-releases/detail/466/castle-biosciences-supports-nationwide-patient-advocacy-and-screening-initiatives-to-celebrate-skin-cancer-awareness-month Tue, 05 May 26 07:00:00 -0400 https://ir.castlebiosciences.com/news-events/press-releases/detail/466/castle-biosciences-supports-nationwide-patient-advocacy-and-screening-initiatives-to-celebrate-skin-cancer-awareness-month https://ir.castlebiosciences.com/news-events/press-releases/detail/465/new-data-at-ddw-2026-show-tissuecypher-testing-improves-risk-stratification-and-drives-risk-aligned-management-in-barretts-esophagus Mon, 04 May 26 07:00:00 -0400 https://ir.castlebiosciences.com/news-events/press-releases/detail/465/new-data-at-ddw-2026-show-tissuecypher-testing-improves-risk-stratification-and-drives-risk-aligned-management-in-barretts-esophagus https://ir.castlebiosciences.com/news-events/press-releases/detail/464/castle-biosciences-to-present-new-data-demonstrating-decisiondx-melanomas-ability-to-identify-patients-with-greater-risk-of-recurrence-and-poor-outcomes-within-early-stage-melanoma-at-eado-and-acms Tue, 21 Apr 26 07:00:00 -0400 https://ir.castlebiosciences.com/news-events/press-releases/detail/464/castle-biosciences-to-present-new-data-demonstrating-decisiondx-melanomas-ability-to-identify-patients-with-greater-risk-of-recurrence-and-poor-outcomes-within-early-stage-melanoma-at-eado-and-acms